Oculis Holding AG (OCS) Non Operating Interest Expenses (2022 - 2026)

Oculis Holding AG's (OCS) quarterly Non Operating Interest Expenses came in at -$220921.8 in Q1 2026, up 19.58% year-on-year from -$184741.0 in Q1 2025, and up 26.73% quarter-over-quarter from -$301531.9 in Q4 2025.

Oculis Holding AG (OCS) Non Operating Interest Expenses (2022 - 2026) Analysis & Trends

Oculis Holding AG's Non Operating Interest Expenses history runs 5 years deep, the most recent figure standing at -$220921.8 for Q1 2026.

  • On a quarterly basis, Non Operating Interest Expenses rose 19.58% year-over-year to -$220921.8 in Q1 2026; TTM through Mar 2026 was -$203.3 million, a 33.44% increase from a year earlier, with the FY2025 full-year figure at -$1.0 million, down 38.32% from the prior year.
  • Non Operating Interest Expenses climbed to -$220921.8 in Q1 2026 per OCS's latest filing, from -$301531.9 in the prior quarter.
  • Across five years, Non Operating Interest Expenses topped out at -$12453.7 in Q3 2023 and bottomed at -$304.7 million in Q3 2024.
  • The 5-year median for Non Operating Interest Expenses is -$278340.9 (2025), against an average of -$32.2 million.
  • Across the five-year window, Non Operating Interest Expenses jumped 99.34% in 2023 and plunged 2446652.74% in 2024, its largest moves.
  • Year by year, Non Operating Interest Expenses stood at -$1.4 million in 2022, then surged by 99.01% to -$13528.3 in 2023, then slumped by 1984.2% to -$281955.9 in 2024, then declined by 6.94% to -$301531.9 in 2025, then increased by 26.73% to -$220921.8 in 2026.
  • Per Business Quant, the three latest OCS Non Operating Interest Expenses figures stand at -$220921.8 (Q1 2026), -$301531.9 (Q4 2025), and -$202.5 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -220,921.81
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn -
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Alnylam Pharmaceuticals 36.08 Bn 33.07 Bn 959.66 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -220,921.81
Dec 31, 2025 -301,531.92
Sep 30, 2025 -202.52 Mn
Jun 30, 2025 -221,043.91
Mar 31, 2025 -274,725.88
Dec 31, 2024 -281,955.90
Sep 30, 2024 -304.71 Mn
Jun 30, 2024 -96,204.03
Mar 31, 2024 -46,972.97
Dec 31, 2023 -13,528.25
Sep 30, 2023 -12,453.68
Jun 30, 2023 -18,906.98
Mar 31, 2023 -1.38 Mn
Dec 31, 2022 -1.37 Mn
Sep 30, 2022 -1.90 Mn
Jun 30, 2022 -1.73 Mn